1910.ai Model Foundry
1910.ai
- Web
5.8 Club score Visit 1910.ai
What the maker publishes
- Access model
- The site presents the platform through flexible partnering models; Model Foundry software-module access via PaaS is listed as in development. source
- Cloud and compute
- ITO is described as cloud-based on Microsoft Azure, with Azure Quantum Elements and Microsoft and NVIDIA partnerships for multi-GPU compute. source
- Data orchestration
- Data Orchestration formats, analyzes, cleans, annotates, curates, and featurizes multimodal data before model ingestion. source
- Federated learning
- Federated learning supports collaborative training across blinded datasets from multiple companies without sharing the datasets themselves. source
- Headquarters
- Boston Seaport source
- Maker history
- 1910 says it was founded in 2018 and is headquartered in Cambridge, Massachusetts. source
- Model capabilities
- The platform includes model evaluation, selection, sampling, training, inference, observability, molecule provenance, alignment, and safety. source
- Model Foundry
- Model Foundry includes hundreds of AI/ML models and a Multi-AI Agent System for drug-discovery optimization. source
- Molecule design
- After data ingestion, the platform produces an in-silico molecule and suggests synthetic routes to support feasibility, yield, and scale-up. source
- Partner audience
- Partnering models are presented for pharma, biotech, venture capital and lab incubators, academia, and government. source
- Privacy approach
- The site says private data remains on local devices or partners' data centers in its federated-learning workflow. source
- Product purpose
- ITO integrates multimodal data, AI models, and lab automation to support small- and large-molecule drug discovery. source
- Supported modalities
- The platform lists small molecules, peptides, and biologics as modalities for federated learning. source
- Target identification
- AI-driven Precision Target ID uses multiomic patient-derived tissue and clinical data to identify novel biological targets. source
Checked against the maker's pages on 14 Nov 2026.